ArticleTranslational pediatrics2026
Global research landscape in pharmacotherapy for autism spectrum disorder core symptoms: a bibliometric study.
Article in Translational pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Autism spectrum disorder (ASD) is a neurodevelopmental condition characterized by social communication deficits and repetitive behaviors. While non-pharmacological interventions are primary, pharmacotherapy targeting core symptoms has gained attention despite challenges from ASD's heterogeneity and limited effective treatments. Bibliometric analysis provides a systematic overview of research trends, especially in early pharmacotherapy development. This study aims to evaluate the global research landscape and trends in pharmacotherapy for the core symptoms of ASD through bibliometric analysis. Methods: This study applied bibliometric methods to analyze 109 English publications [1993-2025] from the Web of Science focusing on ASD pharmacotherapy. Using R (biblioshiny), co-citation, co-word, co-authorship, and source citation analyses were performed to map the global research landscape, identify key contributors, trace thematic evolution, and reveal emerging trends. Results: Findings showed a significant rise in pharmacotherapy research, driven largely by international collaborations, notably involving the USA and Australia. Citation networks centered on neurotransmitter systems (serotonin, dopamine). Four research clusters were identified: (I) repetitive behaviors (risperidone, fluoxetine, melatonin); (II) social behavior/neuropeptides (vasopressin, oxytocin); (III) novel mechanisms (memantine, aripiprazole, atomoxetine); and (IV) adjunctive treatments. Established drugs showed partial efficacy, while new targets and combination strategies gained prominence. Conclusions: This bibliometric study offers a comprehensive view of ASD pharmacotherapy research, highlighting international collaboration and distinct themes. It underscores the need for more targeted, effective, and safe treatments and advocates further research into novel mechanisms, combination therapies, and standardized assessments to improve clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.